Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylprednisolone in Community-Acquired Pneumonia
NCT03745664Phase 3Unknown
- Sponsor
- Sapienza University of Rome
- Start
- Jan 2021
- Primary completion
- May 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of methylprednisolone injection in community acquired pneumonia (CAP) (2 arms), sponsored by Sapienza University of Rome. Primary endpoint: High sensitivity cardiac T troponin at 7 days. Status: unknown.
02
Drugs
methylprednisolone injection
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT03745664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03745664.